A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
about
Epigenetic treatment of solid tumours: a review of clinical trialsGlobal histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?Emerging therapies for adult soft tissue sarcoma.Retroperitoneal liposarcoma: current insights in diagnosis and treatmentTargeted therapy in sarcomas other than GIST tumorsPotential Therapeutic Targets in Uterine Sarcomas.Dinutuximab and PanobinostatHR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.Epigenetics in cancer stem cells.Targeted therapy for soft tissue sarcomas in adolescents and young adults.A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.Panobinostat: first global approval.Epigenetic therapy for solid tumors: from bench science to clinical trials.Newer medical therapies for metastatic soft tissue sarcoma.Therapeutic applications of histone deacetylase inhibitors in sarcoma.Managing sarcoma: where have we come from and where are we going?Systemic Treatment for Adults with Synovial Sarcoma.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors
P2860
Q26773803-7DB7005B-B282-429A-AAAD-A330F71058D9Q26775413-4CEFF89C-7825-46C7-B3E7-B7BB5BF2B9EDQ34659806-3A0396CD-2648-402C-A51D-1B6C055999DAQ35066363-B4F97DE7-D9D9-409B-AE9D-18A8E69A5F6BQ35622367-7318E06D-1932-4A38-AAFA-2787E59A373EQ36245677-8A132020-C3C5-4721-94B1-CEA8BF62CBD8Q36572408-E63D8A67-EF02-4A24-8768-80428755AF55Q37002069-ED15AFDF-914F-4B98-B302-698F71DA5ECDQ37136357-4EB80DED-3A15-460B-A687-1D8ED517655FQ37618640-A6158008-211C-4522-9115-1327118F6A76Q37742014-9F5A01EF-838C-444D-B2A9-0C2ADDB625A2Q38336253-3DB5E05D-00A2-48EA-94F0-928F7DCA6403Q38403118-3E094B62-184F-421A-A6B3-A3A9B16F3AA3Q38459836-D75031B0-C82E-48BD-9FA1-E25DD5331EDDQ39012067-0B655323-DD47-4B89-B69B-648939DA44DFQ39450827-393A8D98-6F37-468F-88E9-16DB7CB7059FQ41988197-8481DE24-F58E-4368-AF6C-29EF662FEFAEQ52667763-A2B9CA89-DB05-45F1-99D1-1F27C72A94B2Q52671439-EAC9842C-DFA8-44D0-A379-58C1F0CEDD63Q52689154-C200E1EF-C86C-4C64-AF0F-F4423ED016DCQ57570670-C6913C89-6047-427A-9AEE-B9C4479308BE
P2860
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase II trial of panobinost ...... from the French Sarcoma Group
@ast
A phase II trial of panobinost ...... from the French Sarcoma Group
@en
type
label
A phase II trial of panobinost ...... from the French Sarcoma Group
@ast
A phase II trial of panobinost ...... from the French Sarcoma Group
@en
prefLabel
A phase II trial of panobinost ...... from the French Sarcoma Group
@ast
A phase II trial of panobinost ...... from the French Sarcoma Group
@en
P2093
P2860
P50
P356
P1476
A phase II trial of panobinost ...... from the French Sarcoma Group
@en
P2093
A Italiano
A-C Cadore
C Chevreau
P2860
P2888
P304
P356
10.1038/BJC.2013.442
P407
P577
2013-08-06T00:00:00Z
P5875
P6179
1008727000